Odyssey bails on public listing as US IPO landscape stutters
Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.
Business & Regulation
Pharma’s AI prospects get nudged into the future with EU’s AI act
EU Health Data Space strikes a chord in EU harmonisation plans
EU reshapes HTAs: is the industry ready for it?
Sanofi increases ownership stake partaking in pharma buyback trend
Flu vaccine strategy on the line as new US leaders anticipated to take charge
US Border Protection warns pharma of risks with incorrect biologic importation
WuXi debates sale of pharma operations as BIOSECURE Act advances
